Advertisement
Product › Details
mGlu4 PAM (positive allosteric modulators targeting metabotropic glutamate receptor 4)
Next higher product group | positive allosteric modulator (PAM) | |
Status | development pp | |
Record changed: 2023-07-10 |
Advertisement
More documents for positive allosteric modulator (PAM)
- [1] Cadent Therapeutics. (12/17/20). "Press Release: Cadent Therapeutics Enters Agreement to Be Acquired by Novartis". Cambridge, MA....
- [2] Cadent Therapeutics. (11/15/18). "Press Release: Cadent Therapeutics Secures $40 Million Series B Financing to Advance Pipeline of Novel Therapies for Movement and Cognitive Disorders". Cambridge, MA....
- [3] Addex Therapeutics S.A.. (4/30/18). "Press Release: Addex Reports 2017 Full Year Results and Provides Corporate Update". Geneva....
- [4] Addex Therapeutics S.A.. (2/7/18). "Press Release: Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management". Geneva....
- [5] Addex Therapeutics S.A.. (2/5/18). "Press Release: Addex Provides Key Financial Indicators and Trading Update. Cash Position of CHF6.5 million as of 31 January 2018". Geneva....
- [6] Addex Therapeutics S.A.. (1/3/18). "Press Release: Addex and Indivior Sign Strategic Partnership to Accelerate Development of GABAB PAMs as Addiction Treatments". Geneva....
- [7] Addex Therapeutics S.A.. (2/28/17). "Press Release: Addex Raises CHF3.0 million through Private Placement of Treasury Shares and Extends Cash Runway through 2018". Geneva....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top